GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
|
Synonyms: P3A | SYN-004
Compound class:
Peptide
Comment: Ribaxamase is an orally delivered β-lactamase enzyme, under clinical development as a protective agent against dysbiosis of the gastrointestinal tract caused by some antibacterial drugs [1]. The peptide sequence for ribaxamase is available from its INN record.
|
| No information available. |
Summary of Clinical Use  |
| Disruption of the gut microbiome caused by certain antibacterial drugs is associated with an increase in susceptibility to opportunistic pathogens such as Clostridium difficile. Published results from a Phase 2 study indicate that ribaxamase has the potential to prevent C. difficile infection in patients treated with intravenous β-lactam antibacterials [2]. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT02419001 | A Study to Evaluate the Effect of SYN-004 on the PK of IV Ceftriaxone in Adults With a Functioning Ileostomy | Phase 1/Phase 2 Interventional | Theriva Biologics, Inc. | 3 | |
| NCT02473640 | A Study Evaluating the Effect of Esomeprazole on SYN-004 Degradation of Ceftriaxone In Adults With an Ileostomy | Phase 1/Phase 2 Interventional | Theriva Biologics, Inc. | 3 | |
| NCT04692181 | SYN-004 Safety and Tolerability in Allo-HCT Subjects | Phase 1/Phase 2 Interventional | Theriva Biologics, Inc. | ||
| NCT02563106 | A Study of SYN-004 for the Prevention of C.Diff in Patients With a LRTI | Phase 2 Interventional | Theriva Biologics, Inc. | 2 | |
